ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 615

The Comparative Observational Study about Efficacy, Safety and Adherence between Tocilizumab and Infliximab in Patients with Rheumatoid Arthritis

Mayumi Matsuda1, Yu Funakubo Asanuma2, Yoshinobu Nakao3, Hiroaki Yazawa2, Takuma Tsuzuki Wada4, Noritsune Kouzu5 and Toshihide Mimura2, 1Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, 2Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 3Department of Rheumatology, Saga University Hospital, Saga, Japan, 4Department of Rheumatology and Applied Immunology, Faculty of Medicine,, Saitama Medical University, Saitama, Japan, 5Saitama Medical University, Moroyama, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: infliximab, rheumatoid arthritis (RA) and tocilizumab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Since 2003 in Japan, biologic agents have become widely used for RA patients in whom csDMARDs were ineffective. Tocilizumab (TCZ) was approved for marketing for use in patients with RA in Japan ahead of other countries in 2008. Randomized controlled trials have been shown the efficacy and safety of TCZ in patients with RA. Infliximab (IFX) is the first approved TNF inhibitor in Japan and it has abundant evidences for RA treatment. There have been few reports about the head to head comparison between IL-6 inhibitor and TNF inhibitors in patients with RA. We investigated the efficacy, safety, and adherence in RA patients treated with TCZ or IFX in real clinical practice.

Methods: One hundred sixty-one patients with RA treated with TCZ or IFX were retrospectively observed for 12 months in Saitama Medical University Hospital since 2008 to 2016. We compared the baseline characteristics, disease activity, physical disability, drug continuation rate, and adverse events between the patients treated with TCZ or IFX.

Results: In TCZ group (n=89) compared with IFX group (n=72), we found longer disease duration (TCZ vs. IFX: 9.8 vs. 6.4years p=0.001), lower rate of biologic-naïve patients (27.0% vs. 94.4% p<0.001), fewer MTX-users (66.3% vs. 100% p<0.001), and lower dose of MTX (5.8 vs. 8.5mg/week p<0.001). Age of disease onset, rate of female, DAS28-ESR4, HAQ-DI, RF, MMP-3, and daily dose of PSL were similar between the groups. DAS28-ESR4 and HAQ-DI significantly decreased for one year in both groups. The patients who achieved remission or low disease activity in CDAI were more in TCZ group than IFX group (83.8% vs. 62.5% p=0.016). There was no significant difference in the drug continuation rate (80.9% vs. 75.0%). In the patients who discontinued TCZ or IFX during one year of observational period, the rate of adverse events or lack of efficacy was not significantly different between the groups. We also investigated the efficacy, safety and drug continuation rate of TCZ (n=24) or IFX (n=68) as a first biologic for RA. The prevalence of patients who achieved remission or low disease activity in CDAI were more in TCZ group than IFX group (95.0% vs. 61.7% p=0.007), and there was no significant difference in the drug continuation rate (83.3% vs. 77.9%). The rate in lack of efficacy was lower in TCZ group than IFX group (0% vs. 10.3%) and there was no difference in adverse events between the groups (16.7% vs. 11.8%).

Conclusion: TCZ-treated patients, who, despite, had longer disease duration, were less biologic-naïve, and fewer MTX-users, showed equivalent or greater efficacy, drug continuation rate, and safety comparing with those treated with IFX.


Disclosure: M. Matsuda, None; Y. F. Asanuma, None; Y. Nakao, None; H. Yazawa, None; T. T. Wada, None; N. Kouzu, None; T. Mimura, None.

To cite this abstract in AMA style:

Matsuda M, Asanuma YF, Nakao Y, Yazawa H, Wada TT, Kouzu N, Mimura T. The Comparative Observational Study about Efficacy, Safety and Adherence between Tocilizumab and Infliximab in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-comparative-observational-study-about-efficacy-safety-and-adherence-between-tocilizumab-and-infliximab-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-comparative-observational-study-about-efficacy-safety-and-adherence-between-tocilizumab-and-infliximab-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology